IRIS Accounts Production v25.1.3.33 04077549 director 1.4.24 31.3.25 31.3.25 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh040775492024-03-31040775492025-03-31040775492024-04-012025-03-31040775492023-03-31040775492023-04-012024-03-31040775492024-03-3104077549ns15:EnglandWales2024-04-012025-03-3104077549ns14:PoundSterling2024-04-012025-03-3104077549ns10:Director12024-04-012025-03-3104077549ns10:PrivateLimitedCompanyLtd2024-04-012025-03-3104077549ns10:SmallEntities2024-04-012025-03-3104077549ns10:AuditExempt-NoAccountantsReport2024-04-012025-03-3104077549ns10:SmallCompaniesRegimeForDirectorsReport2024-04-012025-03-3104077549ns10:SmallCompaniesRegimeForAccounts2024-04-012025-03-3104077549ns10:FullAccounts2024-04-012025-03-3104077549ns5:CurrentFinancialInstruments2025-03-3104077549ns5:CurrentFinancialInstruments2024-03-3104077549ns5:ShareCapital2025-03-3104077549ns5:ShareCapital2024-03-3104077549ns5:RetainedEarningsAccumulatedLosses2025-03-3104077549ns5:RetainedEarningsAccumulatedLosses2024-03-3104077549ns10:RegisteredOffice2024-04-012025-03-3104077549ns5:PlantMachinery2024-03-3104077549ns5:PlantMachinery2024-04-012025-03-3104077549ns5:PlantMachinery2025-03-3104077549ns5:PlantMachinery2024-03-3104077549ns5:CostValuation2024-03-3104077549ns5:CostValuation2025-03-3104077549ns5:AdditionsToInvestments2025-03-3104077549ns5:WithinOneYearns5:CurrentFinancialInstruments2025-03-3104077549ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3104077549ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2025-03-3104077549ns5:Non-currentFinancialInstrumentsns5:AfterOneYear2024-03-31
REGISTERED NUMBER: 04077549 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2025

for

PHARMAC LIMITED

PHARMAC LIMITED (REGISTERED NUMBER: 04077549)






Contents of the Financial Statements
for the Year Ended 31 March 2025




Page

Balance Sheet 1

Notes to the Financial Statements 3


PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Balance Sheet
31 March 2025

31.3.25 31.3.24
Notes £    £    £   
FIXED ASSETS
Tangible assets 4 1,038 33,461
Investments 5 333,359 333,358
Investment property 6 840,000 700,000
1,174,397 1,066,819

CURRENT ASSETS
Debtors 7 1,094,093 616,592
Investments 8 86,538 239,973
Cash at bank 190,649 338,167
1,371,280 1,194,732
CREDITORS
Amounts falling due within one year 9 144,922 58,152
NET CURRENT ASSETS 1,226,358 1,136,580
TOTAL ASSETS LESS CURRENT LIABILITIES 2,400,755 2,203,399

PROVISIONS FOR LIABILITIES 73,707 40,935
NET ASSETS 2,327,048 2,162,464

PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Balance Sheet - continued
31 March 2025

31.3.25 31.3.24
Notes £    £    £   
CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 2,326,948 2,162,364
SHAREHOLDERS' FUNDS 2,327,048 2,162,464

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 30 May 2025 and were signed by:





M Ayton - Director


PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Notes to the Financial Statements
for the Year Ended 31 March 2025

1. STATUTORY INFORMATION

Pharmac Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 04077549

Registered office: 16 Hartfield Road
Forest Row
RH18 5DN

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment 33% on cost
Motor Vehicles 25% reducing balance

Investments in subsidiaries and associates
Investments in associates are recognised at cost.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 April 2024 63,689
Additions 491
Disposals (60,158 )
At 31 March 2025 4,022
DEPRECIATION
At 1 April 2024 30,228
Charge for year 5,893
Eliminated on disposal (33,137 )
At 31 March 2025 2,984
NET BOOK VALUE
At 31 March 2025 1,038
At 31 March 2024 33,461

5. FIXED ASSET INVESTMENTS
Shares in Interest
group in
undertakings associate Totals
£    £    £   
COST
At 1 April 2024 25 333,333 333,358
Additions 1 - 1
At 31 March 2025 26 333,333 333,359
NET BOOK VALUE
At 31 March 2025 26 333,333 333,359
At 31 March 2024 25 333,333 333,358

PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

6. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 April 2024 700,000
Revaluations 140,000
At 31 March 2025 840,000
NET BOOK VALUE
At 31 March 2025 840,000
At 31 March 2024 700,000

The investment properties have not been depreciated which is a departure from the Companies Act. This is because departure from the Act is necessary to give a true and fair view.

The investment properties are carried at their fair value.

Fair value at 31 March 2025 is represented by:
£   
Valuation in 2015 129,125
Valuation in 2017 50,000
Valuation in 2023 100,000
Valuation in 2025 140,000
Cost 420,875
840,000

If Investment property had not been revalued it would have been included at the following historical cost:

31.3.25 31.3.24
£    £   
Cost 420,875 420,875

Investment property was valued on an open market basis on 20 February 2025 by Lawson Commercial .

PHARMAC LIMITED (REGISTERED NUMBER: 04077549)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2025

7. DEBTORS
31.3.25 31.3.24
£    £   
Amounts falling due within one year:
Trade debtors 548,059 209,942
Other debtors 246,897 163,724
794,956 373,666

Amounts falling due after more than one year:
Other debtors 299,137 242,926

Aggregate amounts 1,094,093 616,592

8. CURRENT ASSET INVESTMENTS
31.3.25 31.3.24
£    £   
Listed investments 86,538 239,973

9. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.25 31.3.24
£    £   
Trade creditors 122,747 49,388
Taxation and social security 22,175 8,640
Other creditors - 124
144,922 58,152

10. RELATED PARTY DISCLOSURES

During the year, total dividends of £40,000 (2024 - £70,000) were paid to the director .

During the year ended 31 March 2025 rent of £21,708 (31 March 2024 - £21,500) was paid by the company to the company SSAS for rental of Freehold property.

At 31 March 2025 Pharmac Limited was owed £310,000 from the SSAS and in the year ended 31 March 2025 charged £14,411loan interest to the SSAS.

11. ULTIMATE CONTROLLING PARTY

The controlling party is M Ayton.